{"id":474145,"date":"2021-04-09T08:03:10","date_gmt":"2021-04-09T12:03:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=474145"},"modified":"2021-04-09T08:03:10","modified_gmt":"2021-04-09T12:03:10","slug":"seagen-to-highlight-data-from-novel-targeted-therapies-at-aacr","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/seagen-to-highlight-data-from-novel-targeted-therapies-at-aacr\/","title":{"rendered":"Seagen to Highlight Data from Novel Targeted Therapies at AACR"},"content":{"rendered":"

<\/p>\n

Seagen to Highlight Data from Novel Targeted Therapies at AACR<\/b><\/p>\n

-Data Showcase Depth of Oncology Pipeline Using Seagen\u2019s Innovative Technologies-<\/i><\/p>\n

BOTHELL, Wash.–(BUSINESS WIRE<\/a>)–
\nSeagen Inc. (Nasdaq: SGEN) today announced that preclinical data from its pipeline of novel targeted oncology drugs will be presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 10-15, 2021. The oral and poster presentations will highlight several early-stage programs utilizing Seagen\u2019s leading antibody-drug conjugate (ADC) technology as well as its proprietary sugar-engineered antibody (SEA) technology.\n<\/p>\n

\n\u201cOur research being presented at AACR describes intriguing preclinical data for three novel pipeline programs that are in ongoing clinical trials. This includes SEA-TGT, an anti-TIGIT antibody using our SEA technology, and two vedotin-based ADCs, SGN-B6A and SGN-STNV. We believe these three programs represent potential best-in-class or first-in-class targeted therapies for cancer,\u201d said Roger Dansey, M.D., Chief Medical Officer at Seagen. \u201cAmong the findings, we will show the enhanced therapeutic effect in combining SEA-TGT with a checkpoint inhibitor or a vedotin-based ADC across different tumor models. In addition, we will report for the first time our preclinical data with SGN-STNV, a novel ADC targeting a carbohydrate antigen that may have broad applicability across solid tumors.\u201d\n<\/p>\n

Highlights of Seagen Programs Presented at AACR<\/i><\/b><\/p>\n

SEA-TGT<\/b><\/p>\n

\nPreclinical data will be presented for SEA-TGT, a novel investigational nonfucosylated human IgG1 TIGIT antibody, which utilizes Seagen\u2019s proprietary SEA technology that enhances functionality by targeting key immune activating Fc receptors. TIGIT is an inhibitory immune checkpoint that has emerged as a clinically relevant immuno-oncology target. The monotherapy and combinatorial activity of SEA-TGT was assessed and compared to TIGIT monoclonal antibodies (mAbs) with inert, standard, or effector function modified backbones in vivo<\/i> and in vitro.<\/i> Key preclinical findings were as follows:\n<\/p>\n